While 2023 may have been the year of AI for the consumer consciousness, for companies using the technology in a focused way in drug development it was just another year of learning and advancing, as is 2024.
On Day One of the JP Morgan Healthcare Conference this month, editor-in-chief Jonah Comstock caught up with Jen Nwankwo, CEO of 1910 Genetics, a biotech advancing small and large molecule drug discovery with multimodal AI, to talk about the potential of the technology for improving R&D productivity, which Nwankwo points out has been declining for years.
They discuss how AI-powered companies can stand out in a crowded field and some of the ways 1910 is using AI, from early-stage computer modelling to robotics-enabled laboratory automation. They also talk about the regulatory landscape around AI drug discovery, and Nwankwo shares her predictions for biotech in 2024, including M&A, the future of big tech in pharma, IPOs, and more.
Don’t miss this engaging sit down with an up-and-coming AI-powered biotech in the video here.